Pharmacology

HIV Post Exposure Prophylaxis

A Comprehensive Article

Infections

HIV Post-Exposure Prophylaxis (PEP) is a short-term antiretroviral treatment administered to reduce the risk of HIV infection following potential occupational exposure in healthcare settings. In Ghana, prompt initiation within 1-2 hours (and no later than 72 hours) post-exposure is crucial for effectiveness, particularly for healthcare personnel at risk from needle-stick injuries or mucous membrane contact.

๐Ÿฆ  Overview and Pathophysiology

PEP prevents HIV establishment after exposure to infected blood or body fluids:

Causes of Exposure

  • Percutaneous: Needle-stick or cut with sharp object
  • Mucocutaneous: Contact with mucous membranes or non-intact skin
  • Risk Factors: Large volume of blood, advanced HIV in source, deep injury

Risk Levels

  • Very Low: Intact skin exposure
  • Low: Small volume from asymptomatic patient, superficial injury
  • High: Large volume, high viral load source, hollow bore needle
  • Key Point: Risk ~0.3% for percutaneous, lower for mucous

๐Ÿ” Risk Assessment

Immediate evaluation post-exposure is essential:

Steps to Prevent Transmission

Wound Care: Clean with soap and water
Mucous Membranes: Flush with water or saline
Assess Risk: Classify as very low, low, or high based on exposure type and source

Immediate Actions:
  • Report to supervisor and document exposure
  • Counsel and test exposed worker and source patient
  • Initiate PEP within 1-2 hours if indicated

๐Ÿงช Investigations

Baseline and follow-up tests to monitor sero-status and toxicity:

Time Point Tests
BaselineFull blood count, Liver and renal function tests, Hepatitis B Surface Antigen, HIV serology or PCR
Two weeksFull blood count, Liver and renal function tests
Six weeksHIV serology
Three monthsHIV serology
Six monthsHIV serology
Clinical Insight: Sero-converters should access comprehensive care and ART.

๐Ÿ’Š Treatment

Objectives: Prevent HIV infection establishment. Timing: Initiate promptly, preferably within 1-2 hours, not beyond 72 hours.

Non-Pharmacological

Counselling: Immediate and ongoing; emphasize safe sex and condom use
Source Testing: Counsel and test source patient if status unknown
Documentation: Record exposure details, management, and follow-ups

Very Low Risk

  • Treatment: Wash exposed area with soap and water
  • Evidence: [A]

Low Risk

  • Preferred: Tenofovir 300 mg daily + Emtricitabine 200 mg daily for 28 days
  • Alternative: Zidovudine 300 mg 12 hourly + Lamivudine 150 mg 12 hourly for 28 days

High Risk

  • Preferred: Tenofovir 300 mg daily + Emtricitabine 200 mg daily + Lopinavir/r 400/100 mg 12 hourly for 28 days
  • Alternative: Zidovudine 300 mg 12 hourly + Lamivudine 150 mg 12 hourly + Lopinavir/r 400/100 mg 12 hourly for 28 days
Important Notes:
  • If source is HIV/HBV co-infected, use Tenofovir-containing regimen
  • Monitor for drug toxicity and HIV sero-conversion
  • Refusal of testing should be documented

๐Ÿ“ Reporting and Documentation

All exposures must be reported and documented:

Required Details

Incident: Date, time, location, how it occurred, exposure site, device type
Exposure: Type and amount of fluid, severity
Source: Status, clinical details
Exposed Worker: Medical conditions, vaccinations (e.g., Hepatitis B), medications, pregnancy/breast-feeding

Note: Include counselling, PEP management, and follow-ups in records.

๐Ÿšจ Referral Criteria

Immediate Referral:
  • Sero-conversion or positive HIV test post-exposure
  • Adverse drug reactions or complications
  • Access to comprehensive care and ART services

Refer to accredited treatment centres in Ghana.

๐Ÿง  Key Takeaways

  • โœ… Act Fast: Initiate PEP within 1-2 hours, max 72 hours
  • โœ… Risk Stratify: Very low (wash only), low/high (ART regimens)
  • โœ… Counsel & Test: Exposed worker and source; ongoing support
  • โœ… Monitor: Baseline/follow-up tests for toxicity and sero-status
  • โœ… Document: All details for reporting and follow-up
  • โœ… Special: Tenofovir for HBV co-infection